Investors: News
Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update
- Continued advancement across clinical and preclinical programs; on track with multiple milestones and key data readouts expected through the second half of 2022 - Company has sufficient capital to fund operations beyond mid-2024 HOUSTON, Aug. 15, 2022 -- Moleculin...
Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
- Preliminary Phase 1b data demonstrated clinical activity, defined as stable disease or better - Company determines RP2D to be 360 mg/m2 and will begin Phase 2 recruitment - Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of...
Moleculin Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
- Preliminary results of second cohort in the first-in-human Phase 1a allow Company to proceed to 32 mg/kg dose of WP1122 in third cohort toward establishing maximum tolerated dose (MTD) -- Multiple ascending dose (MAD) cohort to commence after completion of at least...
Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
- Preliminary results of first cohort in the first-in-human Phase 1a allows Company to proceed to 16 mg/kg dose of WP1122 in second cohort toward establishing maximum tolerated dose (MTD) - - Multiple ascending dose (MAD) cohort to commence after completion of at...
Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
- Single ascending dose (SAD) cohort of first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 and establish maximum tolerated dose - - Multiple ascending dose (MAD) cohort to commence after completion of at least 3 SAD dosing cohorts in which...
Moleculin to Present at the H.C. Wainwright Global Investment Conference
HOUSTON, May 19, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp,...
Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update
- Positive advancements, encouraging preclinical and clinical data, and development activity in all three core technologies - - Multiple key clinical and regulatory milestones expected throughout 2022 - - Company has sufficient capital to fund operations into 2024 -...
Moleculin Receives Approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
- Dosing for first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 in healthy volunteers and establish maximum tolerated dose expected to commence imminently - HOUSTON, May 10, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or...
Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
- Preliminary positive safety and efficacy data from second Phase 1 AML study validate advancement to Phase 1/2 of Annamycin in combination with Cytarabine - Preclinical animal research demonstrated a 68% increase in OS with Annamycin and Cytarabine combined compared...
Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer
Global leader with a distinguished 30-year career in oncology, hematology, and academia with significant contributions in clinical developments in ovarian cancer, lung cancer, and leukemias and lymphomas Company continues to advance clinical development across...